Senti Biosciences Holdings Inc (SNTI)

Currency in USD
0.3886
-0.0474(-10.87%)
Closed·
0.3885-0.0001(-0.03%)
·
Unusual trading volume
Earnings results expected tomorrow
SNTI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.36000.4400
52 wk Range
0.33312.8800
Key Statistics
Prev. Close
0.436
Open
0.436
Day's Range
0.36-0.44
52 wk Range
0.3331-2.88
Volume
757.54K
Average Vol. (3m)
258K
1-Year Change
-76.3769%
Book Value / Share
-0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SNTI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.5000
Upside
+3,374.01%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.5000
(+3,374.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy12.00+2,988.01%-MaintainMar 27, 2026
Leerink Partners
Buy6.00+1,444.00%-New CoverageNov 21, 2025
H.C. Wainwright
Buy12.00+2,988.01%-New CoverageOct 14, 2025

Earnings

Latest Release
May 14, 2026
EPS / Forecast
-0.14 / -0.42
Revenue / Forecast
8K / --
EPS Revisions
Last 90 days

SNTI Income Statement

Compare SNTI to Peers and Sector

Metrics to compare
SNTI
Peers
Sector
Relationship
P/E Ratio
−0.2x−7.8x−0.4x
PEG Ratio
0.00−0.030.00
Price / Book
−3.6x4.2x2.6x
Price / LTM Sales
220.1x17.7x3.1x
Upside (Analyst Target)
-97.2%48.9%
Fair Value Upside
Unlock7.2%6.2%Unlock

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
789.60K2.54%306.84K
Other Institutional Investors
25.01M80.31%9.72M
Public Companies & Retail Investors
5.34M17.15%2.08M
Total
31.14M100.00%12.1M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Celadon Partners31.39%9,777,0003,799
New Enterprise Associates 15, L.P.12.12%3,775,6151,467

People Also Watch

1.3000
QUCY
-4.41%
13.29
AMPL
+2.78%
17.110
MRAM
+0.82%
3.310
MX
+0.91%
5.720
SATL
+7.92%

FAQ

What Is the Senti Biosciences (SNTI) Stock Price Today?

The Senti Biosciences stock price today is 0.3886 USD.

What Stock Exchange Does Senti Biosciences Trade On?

Senti Biosciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Senti Biosciences?

The stock symbol for Senti Biosciences is "SNTI."

What Is the Senti Biosciences Market Cap?

As of today, Senti Biosciences market cap is 12.1000M USD.

What Is Senti Biosciences's Earnings Per Share (TTM)?

The Senti Biosciences EPS (TTM) is -1.7136.

When Is the Next Senti Biosciences Earnings Date?

Senti Biosciences will release its next earnings report on Aug 24, 2026.

From a Technical Analysis Perspective, Is SNTI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Senti Biosciences Stock Split?

Senti Biosciences has split 1 times.

How Many Employees Does Senti Biosciences Have?

Senti Biosciences has 39 employees.

What is the current trading status of Senti Biosciences (SNTI)?

As of Aug 23, 2026, Senti Biosciences (SNTI) is trading at a price of 0.3886 USD, with a previous close of 0.4360 USD. The stock has fluctuated within a day range of 0.3600 USD to 0.4400 USD, while its 52-week range spans from 0.3331 USD to 2.8800 USD.

What Is Senti Biosciences (SNTI) Price Target According to Analysts?

The average 12-month price target for Senti Biosciences is 13.5000 USD, with a high estimate of 15 USD and a low estimate of 12 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +3,374.01% Upside potential.

What Is the SNTI Premarket Price?

SNTI's last pre-market stock price is 0.4400 USD. The pre-market share volume is 64,820.0000, and the stock has decreased by 0.0040, or 0.9200%.

What Is the SNTI After Hours Price?

SNTI's last after hours stock price is 0.3885 USD, the stock has decreased by -0.0001, or -0.0300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.